Abstract:Hematopoietic stem cell transplantation (HSCT) is an important approach to curing a variety of benign and malignant hematopoietic and non-hematopoietic system diseases. As clinicians, we should raise the awareness of potential gynecologic and reproductive health issues that may occur in female patients before and after HSCT, such as human papillomavirus (HPV) infection, abnormal uterine bleeding, premature ovarian insufficiency (POI), fertility preservation, hormone replacement therapy and induction of puberty, and chronic graft-versus-host disease (cGVHD), thus promoting the full life cycle medical management of HSCT patients.